Abstract: Stabilized TCR constructs comprising a TCR alpha chain polypeptide having a variable alpha (V?) domain and a constant alpha (C?) domain and a TCR beta chain polypeptide having a variable beta (V?) domain and a constant beta (C?) domain. The TCR constructs are stabilized by the introduction into the C? domain and/or the C? domain of stabilizing mutations such as non-naturally occurring disulfide bonds between the C? domain and the C? domain (an interchain disulfide bond), non-naturally occurring intrachain disulfide bonds, point mutations, loop truncation mutations, and combinations thereof. TCR fusion proteins comprising one or more of the TCR constructs and a scaffold and/or other biologically active moiety are also described.

Abstract: Described herein are antibody constructs comprising a 4- 1BB binding domain and an anti-Folate Receptor a (FRa) antigen- binding domain, wherein the 4-1BB-binding domain and the FR? antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function. The antibody constructs are used in the treatment of a subject having cancer.

Abstract: Described herein are antibody constructs comprising a 41-1BB binding domain and an antigen-binding domain that binds to a tumor-associated antigen (TAA), wherein the 4-1BB-binding domain and the TAA antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function.